Sodium-glucose co-transporter 2 (SGLT2) inhibitors block glucose reabsorption in the renal
proximal tubule, an insulin-independent mechanism that plays a critical role in glycemic …

Patients with diabetes are at higher risk of cardiovascular diseases and cognitive
impairment. SGLT2 inhibitors (Empagliflozin, Canagliflozin, Dapagliflozin, Ertugliflozin …

There is a close relationship between diabetes mellitus and heart failure, and diabetes is an
independent risk factor for heart failure. Diabetes and heart failure are linked by not only the …

Background Sodium–glucose transporter 2 inhibitors (SGLT2-I) could modulate
atherosclerotic plaque progression, via down-regulation of inflammatory burden, and lead to …

Background Innovative GLP-1 receptor agonist (GLP-1RA)-based treatment strategies—
such as tirzepatide, GLP-1RA plus basal insulin fixed-ratio combinations [FRC], GLP-1RA …

Chronic hyperglycemia induces pathophysiologic pathways with negative effects on the
metabolism of most substrates as well as lipids and lipoproteins, and thereby induces …

Abstract Purpose of Review Patients with non-alcoholic fatty liver disease (NAFLD), often
considered as the hepatic manifestation of the metabolic syndrome, represent a population …

Background Sodium–glucose cotransporter 2 (SGLT2) inhibitors constitute the gold
standard treatment for type 2 diabetes mellitus (T2DM). Among them, empagliflozin (EMPA) …

Background Sodium-glucose cotransporter 2 (SGLT2) inhibitors have shown promise in
reducing the risk of atrial fibrillation (AF). However, the results are controversial and the …

This review discusses the evolving topic of atrial cardiomyopathy concerning valvular heart
disease. The pathogenesis of atrial cardiomyopathy involves multiple factors, such as …